Automated Insulin Delivery (AID) systems have demonstrated remarkable benefits in improving time spent within the optimal glucose range for individuals dealing with type 1 diabetes.
However, their efficacy in type 2 diabetes remains relatively unexplored. Let’s delve into the current clinical trials examining the potential of Control-IQ, MiniMed 780G, and Omnipod 5 AID systems in managing type 2 diabetes.
Understanding AID Systems’s Benefits
Recognized for reducing hyperglycemia and enhancing time spent within the target range, AID systems offer promising advantages, simplifying the intricacies of diabetes management across diverse age groups. Their positive impact extends to users of DIY Loop systems and has been observed in various daily activities, including sleep and pregnancy.
Current Investigations
Studies are underway to evaluate the impact of three leading commercial AID systems:
Control-IQ (2IQP)
Clinical Trials Identifier: NCT05785832
Trial Focus: Investigating Control-IQ technology in adults with type 2 diabetes on basal-bolus insulin therapy.
MiniMed 780G
Clinical Trials Identifier: NCT05238142
Trial Focus: Evaluating the effectiveness of MiniMed 780G in adults with insulin-requiring type 2 diabetes.
Omnipod 5 (SECURE-T2D)
Clinical Trials Identifier: NCT05815342
Trial Focus: Assessing the safety and efficacy of Omnipod 5 in adults with type 2 diabetes using insulin.
Must Read CGMs in noncritical care hospitals optimizes glycemic control
Eligibility Criteria
Each trial has specific eligibility criteria tailored to ensure accurate assessments. Participants must meet certain prerequisites related to diabetes duration, insulin therapy, A1C levels, and willingness to participate in study-specific activities. If you or a friend are interested in learning more about CGMs, please fill out the form.
Significance of These Trials
Exploration into AID systems in type 2 diabetes is a pivotal step towards understanding their potential benefits in glucose management. These studies hold promise in offering insights into the safety and effectiveness of AID systems, potentially leading to expanded approvals and tailored treatments for type 2 diabetes in the future.
Read Guide about Wegovy Dosage Guide: The Best Way For Weight Loss
A Glimpse into the Future
The ongoing research might uncover individuals with type 2 diabetes who could benefit immensely from AID systems, especially in specific situations like hospitalization or end-stage kidney disease. Notably, the use of AID in type 2 diabetes shows promise in reducing time spent in unfavorable glucose ranges without escalating insulin requirements or inducing weight gain, according to insights shared by Emory University School of Medicine assistant professor Georgia Davis, who goes by the name Dr. Georgia Davis.
Also read about CGMs for the Health: Miracle or Myth?
As research progresses, the evolving landscape of AID systems could pave the way for enhanced diabetes management strategies tailored to the diverse needs of individuals with type 2 diabetes.
